Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial

• DOI: 10.1186/s12933-022-01584-8
• Publication Date: 2022-08-06T09:06:09Z
• Authors: Andrei C. Sposito; Ikaro Breder; Joaquim Barreto; Jessica Breder; Isabella Bonilha; Marcus Lima; Alessandra Oliveira; Vaneza Wolf; Beatriz Luchiari; Helison R. do Carmo; Daniel Munhoz; Daniela Oliveira; Otavio R. Coelho-...; Otavio R. Coelho; Jose Roberto Mato...; Filipe A. Moura; Luiz Sergio F. de...; Wilson Nadruz; Thiago Quinaglia; Sheila T. Kimura-...
• Keywords: Empagliflozin; Angiology; Evolocumab

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial dysfunction and reduce cardiovascular events in individuals with type diabetes (T2D). Proprotein convertase subtilisin/kexin 9 (PCSK9i) high-risk patients. Whether the addition of PCSK9i to SGLT2i treatment adds benefits is not known.